Episode

Author Interview: Professor Laura Coates, July 2026

Podcast
The IMID Forum
Published
Jul 22, 2026
Duration seconds
1605
Processing state
not_requested
Canonical source
https://soundcloud.com/imidforum/author-interview-professor-3
Audio
https://feeds.soundcloud.com/stream/2365792121-imidforum-author-interview-professor-3.mp3
JSON
/v1/public/podcasts/the-imid-forum-981476/episodes/author-interview-professor-laura-coates-july-2026
Markdown
/podcast/the-imid-forum-981476/author-interview-professor-laura-coates-july-2026.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/the-imid-forum-981476/episodes/author-interview-professor-laura-coates-july-2026/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/the-imid-forum-981476/author-interview-professor-laura-coates-july-2026.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

Join Professor Peter Nash from the Griffith University in Brisbane, and Laura Coates, Professor at the University of Oxford’s Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, as they discuss a recent paper ‘Ixekizumab with tirzepatide achieved greater disease control than ixekizumab alone in adults with psoriatic arthritis and overweight or obesity: Results from a randomized clinical trial’.